Login to Your Account



Losing Weight Yields No Cardio Gain for Some

Europe's CHMP Bounces Vivus' Weight Loss Drug

By Catherine Shaffer
Staff Writer

Friday, October 19, 2012
europe_resized.jpg

Vivus Inc. will appeal a negative opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). The committee recommended against approval of Qsiva (phentermine/topiramate) based on concerns about potential cardiovascular and central nervous system effects over long term use, and other safety issues.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription